Aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs) are heterogeneous with
regard to clinical presentation, proliferative markers, clinical course, and response to …

Survival for patients with aggressive pituitary tumours (APT) and pituitary carcinomas (PC)
has significantly improved following the increasing use of temozolomide (TMZ) since the first …

Background: A growing number of evidences suggest that TMZ applications can generate
impressive benefits for APT and PC patients. However, the definite role of TMZ for …

Although pituitary adenomas (PAs) account for 15% of intracranial tumors, pituitary
carcinomas (PCs) are a rare entity. Most commonly, PCs evolve from aggressive PAs …

Objective To evaluate the long-term outcomes and safety of endoscopic transsphenoidal
surgery (ETS) in recurrent and residual pituitary adenomas (rrPAs), as well as the predictors …

Simple Summary The treatment of aggressive and metastatic pituitary neuroendocrine
tumors (PitNETs) refractory to current therapies, including temozolomide, is challenging and …

The pituitary gland is a potential site for a range of pathologies, for which treatment can
involve resection and/or ionizing radiation. Modern stereotactic radiosurgery (SRS) involves …

Introduction Pediatric pituitary neuroendocrine tumor is a rare condition, and despite
previous research focusing on this specific group, the main factors influencing the surgical …

The rare aggressive pituitary adenoma presents a special challenge, due to the
heterogenous presentation of the disease. The prognosis of aggressive pituitary adenomas …

Aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs) are heterogeneous with
regard to clinical presentation, proliferative markers, clinical course, and response to …